Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

A Bayesian network meta-analysis comparing four oral JAK inhibitors-upadacitinib, abrocitinib, baricitinib, and ivarmacitinib ...

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Analyzing patient health care notes recorded during millions of medical appointments at GPs and hospitals across England has ...

Collaborating institutions in Taiwan report higher risks of atopic disease among children conceived via assisted reproductive technology compared to those conceived naturally.

January 23, 2026 Following the positive COAST 1 results in September 2025, two additional global Phase III studies – SHORE and COAST 2 of amlitelimab, a fully human non-T cell depleting monoclonal ...